AU7023798A - Ricin-like toxin variants for treatment of cancer, viral or parasitic infections - Google Patents
Ricin-like toxin variants for treatment of cancer, viral or parasitic infectionsInfo
- Publication number
- AU7023798A AU7023798A AU70237/98A AU7023798A AU7023798A AU 7023798 A AU7023798 A AU 7023798A AU 70237/98 A AU70237/98 A AU 70237/98A AU 7023798 A AU7023798 A AU 7023798A AU 7023798 A AU7023798 A AU 7023798A
- Authority
- AU
- Australia
- Prior art keywords
- ricin
- cancer
- viral
- nucleic acid
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 101000711303 Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) Mucoricin Proteins 0.000 title abstract 3
- 208000030852 Parasitic disease Diseases 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 244000045947 parasite Species 0.000 abstract 2
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4514897P | 1997-04-30 | 1997-04-30 | |
| US60045148 | 1997-04-30 | ||
| US6371597P | 1997-10-29 | 1997-10-29 | |
| US60063715 | 1997-10-29 | ||
| PCT/CA1998/000394 WO1998049311A2 (en) | 1997-04-30 | 1998-04-30 | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7023798A true AU7023798A (en) | 1998-11-24 |
Family
ID=26722431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU70237/98A Abandoned AU7023798A (en) | 1997-04-30 | 1998-04-30 | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6593132B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0977862B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4566290B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE437229T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU7023798A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2288943C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69840998D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998049311A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US7247715B2 (en) * | 1997-04-30 | 2007-07-24 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| AU7636800A (en) | 1999-10-04 | 2001-05-10 | Twinstrand Therapeutics Inc. | Improved ricin-like toxins for treatment of cancer |
| GB0100551D0 (en) * | 2001-01-09 | 2001-02-21 | Queen Mary & Westfield College | Protein |
| EP1483298A4 (en) | 2002-02-11 | 2007-03-14 | Zymogenetics Inc | MATERIALS AND METHODS FOR PREPARING DIMERED GROWTH FACTORS |
| AU2004257206A1 (en) * | 2003-07-10 | 2005-01-27 | Wyeth Holdings Corporation | Recombinant expression of Streptococcus pyogenes cysteine protease and immunogenic compositions thereof |
| EP1730282A4 (en) * | 2004-03-24 | 2007-05-09 | Twinstrand Therapeutics Inc | GLYCOSYLATION VARIANTS OF RICINE-LIKE PROTEINS |
| ATE467641T1 (de) * | 2004-03-26 | 2010-05-15 | Molecular Templates Inc | Bibliothek von toxin mutanten und deren verwendung |
| US20060024722A1 (en) * | 2004-07-30 | 2006-02-02 | Mark Fischer-Colbrie | Samples for detection of oncofetal fibronectin and uses thereof |
| DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| CA2664549A1 (en) | 2005-09-26 | 2007-03-29 | University Health Network | Library from toxin mutants, and methods of using same |
| DE602006012358D1 (de) * | 2005-11-18 | 2010-04-01 | Dabur Pharma Ltd | Zielgerichtete fusionsproteine für die krebstherapie |
| WO2008157263A2 (en) * | 2007-06-15 | 2008-12-24 | Arkansas State University | Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
| EP2379720B1 (en) | 2009-01-20 | 2016-08-17 | Alona Zilberberg | Mir-21 promoter driven targeted cancer therapy |
| US9321847B2 (en) * | 2010-09-20 | 2016-04-26 | Ramot At Tel Aviv University Ltd. | Activatable toxin complexes comprising a cleavable inhibitory peptide |
| US10513539B2 (en) | 2011-02-10 | 2019-12-24 | Ruprecht-Karls-Universitat Heidelberg | Hydrophobic modified peptides and their use for liver specific targeting |
| CN103402546B (zh) | 2011-02-10 | 2018-04-13 | 海德堡鲁普雷希特卡尔斯大学 | 用于肝特异性诊断的疏水性修饰肽 |
| WO2012123755A1 (en) | 2011-03-17 | 2012-09-20 | The University Of Birmingham | Re-directed immunotherapy |
| JP7134461B2 (ja) * | 2018-03-23 | 2022-09-12 | 国立大学法人金沢大学 | マラリア治療剤、マラリア予防剤及び抗マラリア自然免疫賦活剤 |
| KR102698801B1 (ko) | 2020-12-30 | 2024-08-29 | 호크아이 바이오 리미티드 | 바이오마커 검출을 위한 순수 그래핀 기반 바이오센서 및 관련 코어 입자, 재료 구성 방법 및 시스템 |
| TW202328170A (zh) * | 2021-09-14 | 2023-07-16 | 美商艾希利歐發展股份有限公司 | 可裂解連接子 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2442A (en) | 1842-02-01 | Floating dry-dock | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0145111B1 (en) * | 1983-07-15 | 1990-05-09 | The University Of Warwick | Dna sequence coding for a plant toxin of the ricin type, or a portion thereof |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4869903A (en) | 1987-05-29 | 1989-09-26 | Genelabs Incorporated | Method of selectively inhibiting HIV |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| US5128460A (en) | 1989-04-04 | 1992-07-07 | Genelabs Incorporated | Recombinant trichosanthin and coding sequence |
| US5101025A (en) | 1989-04-04 | 1992-03-31 | Genelabs Incorporated | Recombinant trichosanthin and coding sequence |
| US5248606A (en) * | 1990-06-11 | 1993-09-28 | Dowelanco | Dna encoding inactive precursor and active forms of maize ribosome inactivating protein |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| US5677274A (en) * | 1993-02-12 | 1997-10-14 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Anthrax toxin fusion proteins and related methods |
| EP0909322B1 (en) * | 1996-04-30 | 2005-11-16 | Twinstrand Therapeutics Inc. | Antiviral ricin-like proteins |
-
1998
- 1998-04-30 US US09/403,752 patent/US6593132B1/en not_active Expired - Lifetime
- 1998-04-30 JP JP54643798A patent/JP4566290B2/ja not_active Expired - Lifetime
- 1998-04-30 AT AT98916743T patent/ATE437229T1/de not_active IP Right Cessation
- 1998-04-30 DE DE69840998T patent/DE69840998D1/de not_active Expired - Lifetime
- 1998-04-30 CA CA2288943A patent/CA2288943C/en not_active Expired - Fee Related
- 1998-04-30 AU AU70237/98A patent/AU7023798A/en not_active Abandoned
- 1998-04-30 EP EP98916743A patent/EP0977862B8/en not_active Expired - Lifetime
- 1998-04-30 WO PCT/CA1998/000394 patent/WO1998049311A2/en not_active Ceased
-
2003
- 2003-03-24 US US10/394,511 patent/US7375186B2/en not_active Expired - Fee Related
-
2008
- 2008-04-29 US US12/111,407 patent/US20110144004A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69840998D1 (de) | 2009-09-03 |
| ATE437229T1 (de) | 2009-08-15 |
| EP0977862A2 (en) | 2000-02-09 |
| JP2001523961A (ja) | 2001-11-27 |
| JP4566290B2 (ja) | 2010-10-20 |
| US7375186B2 (en) | 2008-05-20 |
| US20110144004A1 (en) | 2011-06-16 |
| CA2288943C (en) | 2011-02-01 |
| EP0977862B1 (en) | 2009-07-22 |
| CA2288943A1 (en) | 1998-11-05 |
| WO1998049311A3 (en) | 1999-02-11 |
| WO1998049311A2 (en) | 1998-11-05 |
| US6593132B1 (en) | 2003-07-15 |
| EP0977862B8 (en) | 2009-09-16 |
| US20040009551A1 (en) | 2004-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0977862B8 (en) | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections | |
| Gustafson et al. | Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the CyanobacteriumNostoc ellipsosporum | |
| RU2220980C2 (ru) | Химерное антитело, которое связывается с cd40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного т-клетками (варианты), способ лечения больного от заболевания, опосредованного т-клетками (варианты) | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| EP1427744A4 (en) | SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS | |
| NZ583028A (en) | Nucleic acids and proteins from streptococcus groups A & B | |
| GB0121591D0 (en) | Hybrid and tandem expression of neisserial proteins | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| EP1016418A3 (en) | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule | |
| CY1106926T1 (el) | Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της | |
| BR9711457A (pt) | Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas. | |
| ATE453665T1 (de) | Mage-a1 peptide die von klasse ii hla molekule presentiert werden | |
| DE60203692D1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| WO2002072036A3 (en) | Compositions and methods comprising west nile virus polypeptides | |
| SE8703225L (sv) | Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner | |
| DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
| RU94045907A (ru) | Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты | |
| WO2003004683A3 (en) | Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
| EA200100700A1 (ru) | Гены и белки и их применение | |
| CA2252799A1 (en) | Antiviral ricin-like proteins | |
| WO2001025267A3 (en) | Improved ricin-like toxins for treatment of cancer | |
| UY26763A1 (es) | Inmunización del ganado lacteo con proteína gapc quimérica contra infección por estreptococo. | |
| SE9700244D0 (sv) | Novel antibacterial protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |